The approval allows Glycotope Biotechnology to provide its customers with a complete service "from the gene to the drug" at highest technological level. As a unique benefit, we offer our clients the use of our toolbox of human, glycoengineered cell lines (GlycoExpress™) for glycooptimisation of biopharmaceuticals.

Our know-how in controlling glycosylation patterns of antibodies and other therapeutic proteins during cell line development and establishment of production processes is of pivotal importance not only in the development of glycooptimised biotherapeutics but also of biosimilars that need to have the same characteristics as the originator product.